MONTREAL, July 13th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced that Dr. Andrew Vaillant, CSO at Replicor, will present an overview of HBsAg in chronic HBV infection as part of the Online Research Seminars 2020 series hosted by the Baruch S. Blumberg Institute on July 16th, 2020 at 11:00 a.m. EDT.
The presentation is designed with the following goals:
- Understand the state of the art regarding particle production in HBV infection.
- Examine the impact of approved therapies on functional cure.
- Examine the ability of investigational therapies to target HBV subviral particles.
- Provide an update on nucleic acid polymers, their effects and clinical impact.
Dr. Vaillant’s seminar will be made available following its presentation on the company’s website at www.replicor.com/science/conference-presentations.
For further information about registering for the seminar:
For further information on the Baruch S. Blumberg Institute: https://www.blumberginstitute.org/
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.